Toothsi's parent raises ₹90 crore to expand dental care

What did MakeO get for its ₹90 crore raise?

MakeO got cash to expand its offline clinics across India and Southeast Asia, strengthen its Mumbai-area aligner factory, and fund more acquisitions of dental and aligner businesses. The round was led by Singularity AMC, with DSP family office, Genesis and Unispace Ventures. The company also draws on over $100 million previously raised.

Why is MakeO buying clinics instead of just marketing online?

Because the clear-aligner business is shifting to hybrid care that needs physical touchpoints. Online-only sellers in this market have struggled; SmileDirectClub, a US online aligner firm, went bankrupt in 2023. Clinics let MakeO offer scans, consultations, and follow-ups while feeding its Mumbai factory, which can make over a million aligners a year. Scale and efficiency decide who profits as prices fall. Our read: this round bets on owning the full care path, not on digital reach alone.

Why does a dental startup need its own factory?

MakeO's Mumbai-area factory can produce over a million aligners a year, and its products reach dentists and consumers across more than 150 Indian cities plus exports to over 10 countries through the Toothsi and Zenyum networks. Owning manufacturing keeps per-unit costs down as prices fall, which is critical when the clear aligner market is projected to grow from about $467 million in 2025 to $2.83 billion by 2035. The factory also lets it supply its own clinics and acquired chains like Apple Dental, feeding the offline expansion the new funding supports. Our read: the factory is the margin engine that makes the clinic acquisitions affordable at scale.

How does owning clinics change what happens to the money patients pay?

Each visit becomes a direct revenue stream rather than a fee shared with a partner dentist. MakeO says its India business hit breakeven before the Zenyum merger and the combined entity was expected to turn profitable within two quarters. Clinic visits also feed the factory, where in-house production keeps unit costs down as prices fall. Our read: the clinics are where the margin is captured, which is why this round funds more of them rather than more marketing.

What happens to partner dentists when MakeO buys more clinics?

MakeO's model is hybrid, not just owned clinics. It counts around 1,100 partner dentists across 10 countries plus its own 60-plus centres, and it says it will keep evaluating acquisitions of local dental chains. Partner dentists remain a separate channel that feeds the factory without MakeO bearing their clinic costs. Our read: purchases like Apple Dental extend reach into new cities, while partner networks hold the margin, so the two coexist rather than replace each other.

How does MakeO handle the risk of buying clinics that don't fit?

MakeO has made two acquisitions in six months: Apple Dental, a 20-clinic chain in Andhra Pradesh and Telangana for Rs 10.9 crore, and Zenyum, a Singapore-based aligner and oral-care company with a network of partner dentists across 10 countries. Both deals expand its footprint, but they also add integration complexity. The company says it is evaluating more acquisitions of local dental chains and aligner businesses, and it aims to double its offline presence to over 120 centres. Our read: the strategy is to buy proven local chains that already have trained dentists and patients, avoiding the cost and time of building clinics from scratch.

Does the clinic expansion actually make money, or just bigger?

MakeO says its India business was at breakeven before the Zenyum merger and the combined entity was expected to turn profitable within two quarters after the deal. Revenue crossed ₹500 crore and the company is EBITDA profitable, but EBITDA can look healthy while net income lags, as the company itself notes. The new ₹90 crore round funds more clinics, acquisitions, and the factory, all aimed at doubling revenue in two to three years. Our read: the revenue target comes before profit, and the expansion is funded on the bet that scale eventually flips EBITDA into real net earnings.

Can MakeO keep funding its expansion without more debt?

MakeO has raised over $100 million before this round, plus Rs 90 crore now, and it has crossed Rs 500 crore in revenue with EBITDA profitability since early 2026. But EBITDA excludes interest and taxes, so it doesn't show net income or cash flow. The company plans more acquisitions and doubling its offline centres to over 120, which will need capital. Our read: this round is meant to fund the next step, and MakeO will likely raise again or seek debt if acquisitions strain cash flow.

What would tell investors the expansion is working?

Revenue already crossed ₹500 crore and the company is EBITDA profitable, but EBITDA is earnings before interest, taxes, depreciation, and amortization, it can look healthy while net income lags. The test is whether the clinics and acquired chains like Apple Dental, 20 centres in Andhra Pradesh and Telangana, keep the company cash-generative as it doubles offline presence to over 120 centres. If acquisitions strain cash flow, expansion stalls.

What stops a rival from copying this clinic-plus-factory model?

Scale and efficiency decide who profits as prices fall, according to industry analysis. Big players like Align Technology, maker of Invisalign, dominate, and accessible 3D printers now let small labs make aligners in-house, pushing down prices and thinning margins for smaller vendors. MakeO's edge is its network: around 1,100 partner dentists across 10 countries, over 60 clinics, and a factory that can make a million aligners a year. Replicating that requires capital and time, which is why the company keeps raising funds and acquiring chains like Apple Dental and Zenyum instead of building from scratch.

Why is this more than a routine funding announcement?

This round is fuel for an active consolidation plan, not a routine raise. MakeO, which runs the Toothsi brand, has already bought Apple Dental and Singapore's Zenyum, building a network of 1,100 partner dentists across 10 countries. The company also says it is scouting more acquisitions in India and Southeast Asia, signaling it is mid-strategy.

What makes the factory big enough to matter?

MakeO's Mumbai-area plant can make over a million aligners a year, and the company exports to more than 10 countries through its Toothsi and Zenyum networks. That volume is the point: clear-aligner margins thin as prices fall, so who profits is decided by manufacturing scale and efficiency. The factory turns each new clinic and each acquired dental partner into another customer for its own production, which is how owning the full care path pays off. Our read: this is a bet that factory efficiency, not brand reach, will be the durable advantage as the market grows from $467 million in 2025 to a projected $2.83 billion by 2035.

Why is the factory more important than the clinics?

The factory in the Mumbai Metropolitan Region can make over a million aligners a year, and every clinic MakeO buys or partners with becomes a customer for that production. As prices fall, the winner is decided by manufacturing scale and efficiency. The new money goes into both clinics and manufacturing, so the two work together: clinics feed volume to the factory, and factory volume keeps margins alive. Our read: this bet is that factory efficiency, not brand reach, will be the durable edge as the market triples.

Who ultimately pays when aligner prices keep falling?

The pressure lands on whoever cannot match the factory's scale. The market research notes that as white-label and 3D-printed solutions mature, pricing pressure intensifies, and volume deals can thin margins for smaller vendors, making scale and efficiency crucial for profitability. MakeO's answer is its million-aligner-a-year Mumbai plant, which feeds its own clinics and the 1,100 partner dentists across 10 countries. Our read: patients pay less, but the cost falls on small labs and clinics that cannot produce or buy at MakeO's volume.

What would stop MakeO's acquisition plan from working?

The company's EBITDA profitability is a pre-tax, pre-debt, pre-depreciation measure that leaves out what acquisitions actually cost. When MakeO bought Apple Dental it paid in cash and stock, and the Zenyum deal was structured as a merger of comparable revenue scale, meaning integration risk is real. The company says it is evaluating more purchases across India and Southeast Asia while also aiming to double revenue in two to three years. Our read: if the next targets need cash, MakeO will need another round, because this ₹90 crore round is modest against that ambition.

How would another round of funding change the picture?

A second round would change only the timing. MakeO has already raised more than $100 million before this round, plus Rs 100 crore in June 2025, and it is EBITDA profitable. The constraint is not access to capital but whether acquisitions can be completed on acceptable terms and whether the combined business stays cash-generative while doubling offline centres to over 120. The company is exploring selective mergers and partnerships, and any larger targets would likely require additional funding regardless. Our read: MakeO's ambition outruns its current balance sheet, so the next raise is a matter of when, not if.

What would actually force the next fundraise to happen sooner?

The nearest trigger is a cash acquisition. MakeO has raised more than $100 million before this round, plus Rs 100 crore in June 2025, and it is EBITDA profitable, so day-to-day operations are not the pressure point. But the company is still scouting dental and aligner businesses in India and Southeast Asia, and larger targets beyond the scale of Zenyum, which was a merger of comparable revenue, would likely need cash. Our read: another round arrives the moment a target is identified, not when the current money runs out.

What did MakeO gain from buying Apple Dental and Zenyum?

It bought reach it could not have built alone. Apple Dental's 20 clinics in Andhra Pradesh and Telangana took the Toothsi parent beyond big cities into Tier-2 towns. Zenyum, the Singapore firm, added a Southeast Asian network; the combined group now has about 1,100 partner dentists in 10 countries and a manufacturing base abroad.

Why is MakeO betting on clinics when 3D printing is making aligners cheaper to make anywhere?

MakeO's factory in Mumbai can already produce over a million aligners a year, feeding more than 60 clinical centres and 1,100 partner dentists across 10 countries. The company's own experience, and the bankruptcy of online-only seller SmileDirectClub in 2023, show that manufacturing alone does not win this market. Hybrid care that combines scans, consultations and follow-ups is what keeps patients paying. Our read: the clinic network is the moat, and the factory is just the cost advantage behind it.

If clinics are the moat, what makes them hard to copy?

The moat rests on owning the care path, but the evidence also shows why the path is moving. General dentists are increasingly offering aligners, and dental service organisations are entering with white-label aligners, while affordable 3D printers let small labs produce their own trays. The cost of entry keeps falling, and pricing pressure is thinning margins for smaller vendors, which is exactly why scale and efficiency become the deciding factor. Our read: the clinic network is not hard to copy, but a network of over 1,100 partner dentists plus a factory that can produce a million aligners a year is a scale edge that late entrants will struggle to match.

If the clinic network is the moat, why is MakeO still spending on a factory?

The factory in the Mumbai Metropolitan Region can make over a million aligners a year and exports to more than 10 countries through the toothsi and Zenyum networks. The Zenyum acquisition positions India as the manufacturing hub, and the combined group expects early gains to come from supply chain integration. General dentists and dental service organisations can now buy white-label products or print their own trays, so manufacturing alone does not differentiate; it becomes the cost engine that lets MakeO undercut smaller rivals while the clinics capture patients. Our read: the factory exists to make the clinics profitable, not to be the business itself.

If scale is the edge, why is the market so crowded now?

Because the cost of entry has collapsed. General dentists can now train with Align Technology's tools and offer aligners themselves, dental service organisations sell white-label products they don't have to manufacture, and cheap 3D printers let small labs print their own trays. Every one of these players undercuts on price, which is why the evidence says volume and contracts are what thin margins for smaller vendors. Our read: the industry is consolidating toward whoever can pair factory output with clinic access, and the rest get squeezed out.

Is the expansion plan running out of money?

This round of Rs 90 crore adds to over $100 million raised earlier, and the company has said its combined business is EBITDA profitable. But the plan is to double offline centres to over 120 and keep evaluating acquisitions, and new debt is not part of what is reported. Investors clearly think the market is worth it: India's clear aligner market is projected to grow from $466.99 million in 2025 to $2.83 billion by 2035. Our read: this round is to fund the offline push, not to fix a cash problem, and more capital will likely be needed as the clinic count grows.

Who ends up paying when aligner prices keep falling?

The evidence shows smaller vendors feel the squeeze first: volume and contract-based deals thin their margins as white-label and 3D-printed solutions mature. MakeO's counter is scale, pairing a factory that can make over a million aligners a year with more than 1,100 partner dentists across 10 countries. Patients benefit from lower prices in the short run, but the industry is consolidating toward players who can pair manufacturing with clinic access. Our read: the cost lands on independent dentists and small labs, who get cut out as the big networks undercut them.

What must go right for MakeO to double revenue without losing money?

MakeO's combined business has crossed Rs 500 crore in revenue and is EBITDA profitable, but the company is planning to double offline presence to over 120 centres and is still evaluating more acquisitions. The test is whether acquired clinics like Apple Dental's 20 centres keep the business cash-generative while it invests in growth. Our read: doubling revenue while staying cash-positive requires the acquired chains to feed the Mumbai factory's over-a-million-unit capacity, so that clinic growth turns into manufacturing utilisation rather than just more rent and salaries.